Add us as a preferred source
The latest investment rounds, growth loans, and corporate developments in digital health, including an Irish clinical workflow automation platform, a pharma AI decision tool startup, and a diagnostic imaging network.
Healf secures venture investment led by SEMCAP Beauty & Wellness
London-headquartered personalised health platform Healf has closed an undisclosed minority venture funding round led by US growth investor SEMCAP Beauty & Wellness.
The financing saw participation from Pentland Ventures, Ami Capital, IRIS, Active Partners, Sequel, Dara5 and high-profile individual backers including supermodels Claudia Schiffer and Natalia Vodianova Arnault, as well as footballer Reece James.
Co-founded in 2020 by chief executive Lestat McCree, Healf combines blood biomarker testing, wearable technology integration and practitioner-led guidance to deliver tailored health and lifestyle recommendations. The platform operates around four core pillars – nutrition, movement, mental health and sleep – aiming to help consumers navigate complex wellness options through personalised data insights.
Operating with a team of under 100 people, the company recently surpassed £100 million in annualised revenue run rate and was named Europe’s fastest-growing business in the Financial Times FT1000 rankings.
Healf will use the fresh capital to accelerate software platform development, expand its biomarker-led diagnostic services and scale its international footprint following its launch in Germany.
“Wellness has a decision problem, not a product problem,” said McCree. “There’s more noise, more opinions and more options than any one person can ever hope to make sense of, which makes finding what works for your own wellbeing more challenging than ever. This investment allows us to build on the trust we’ve already earned and continue developing a more personalised approach that helps people make better decisions about their health.”
Pharosyn raises $3 million seed round
London-based healthtech startup Pharosyn has raised $3 million (£2.3 million) in a seed funding round led by Moonfire Ventures. The round saw participation from Entrepreneur First, Transpose Platform and General Advance.
Co-founded by Cambridge University alumni Stephen Cowley and Joshua Hampson, Pharosyn develops specialised AI infrastructure for pharmaceutical commercial decision-making. The company’s platform embeds into enterprise strategy workflows and helps life sciences teams process complex market dynamics, forecast commercial outcomes and evaluate licensing or portfolio investments.
Pharosyn says that its platform is already deployed across several global pharmaceutical companies, where senior executives use the software daily across portfolio strategy, competitive intelligence, business development, and forecasting functions. The startup will deploy the fresh capital to scale its core engineering team and accelerate product development as it expands its enterprise client base.
“Pharmaceutical companies need custom AI infrastructure to maintain a competitive advantage,” said Cowley. “By dramatically increasing the depth of insight, scope of analysis and speed at which teams can work, our infrastructure helps companies make better decisions about where to allocate resources.”
Full Health Medical secures €3 million seed funding
Dublin-headquartered medtech startup Full Health Medical has raised €3 million (£2.5 million) in a funding round led by Elkstone, the first investment out of the firm’s Elkstone Venture Fund II. The round was also backed by state development agency Enterprise Ireland alongside a syndicate of strategic angel investors.
Co-founded by emergency medicine consultant Ann Shortt and Paul McCarthy, with an executive team led by chief executive Dermot Shortt and chief technology officer Rizwan Saeed, Full Health Medical develops a clinical interpretation and workflow automation platform.
While the proliferation of wearable devices, home testing kits and patient-facing apps has expanded consumer health data, interpreting results safely presents an operational bottleneck for health systems. Full Health Medical’s software uses consultant-authored, evidence-based algorithms to automate data interpretation. This enables a single clinician to review and issue results for hundreds of patients daily without compromising governance or clinical oversight.
The platform manages end-to-end health screening logistics and has already processed more than 500,000 medicals across the UK and Ireland for clients including occupational health provider Medmark. Full Health Medical will deploy the new capital to expand its engineering team and accelerate international growth beyond its core UK and Irish markets.
“Full Health Medical is solving a genuine bottleneck in healthcare: the clinical expertise needed to interpret health data safely and at scale,” said Alan Merriman, co-founder of Elkstone. “The team has built a platform that is both rigorously governed and genuinely scalable, and the results speak for themselves – half a million medicals processed to date, and a client base that already includes some of Ireland’s largest population health programmes.”
Strolll secures £4.3 million Innovate UK backing alongside private investment
Stafford-headquartered medical technology startup Strolll has secured £4.3 million in non-dilutive funding from Innovate UK alongside a private investment round led by venture capital firm IW Capital. The equity round saw participation from US private provider Cleveland Clinic and regional investor Future Planet Capital Regional.
Co-founded by chief executive Jorgen Ellis, Strolll develops software as a medical device (SaMD) delivered through off-the-shelf augmented reality (AR) glasses to provide neurorehabilitation for patients with movement and neurological disorders in clinical and home settings. The new financing comprises two distinct Innovate UK awards alongside more than £1 million in private co-investment to advance two separate product development streams.
The primary £3.6 million Innovate UK innovation loan will fund StrolllAssessment, an AI-driven platform that automates the clinical validation of digital neuro-motor assessments. Capital will support the construction of a dedicated biomechanics lab at the company’s Staffordshire headquarters, mirroring real-world care settings to run concurrent validation studies and compress testing timelines.
Separately, a £700,000 Growth Catalyst Investor Partnerships grant combined with the private equity funding will support StrolllAcute, a bedside-first AR rehabilitation system designed to allow early therapeutic intervention for acute, bed-bound hospital patients without disrupting ward workflows.
“Our team is committed to revolutionising rehabilitation for those living with neurological disorders,” said Ellis. “This funding will help us accelerate our mission to increase patient engagement, support progression and help clinicians deliver effective neurorehabilitation to a wider patient population.”
ViaNautis Bio raises funds from SCI Ventures
London-headquartered biotechnology company ViaNautis Bio has secured an undisclosed investment from SCI Ventures, a specialist venture fund backed by global research foundations focused on advancing treatments for paralysis. The new capital will support the application of ViaNautis’ targeted delivery platform to regenerative genetic therapies for chronic spinal cord injury (SCI).
Spun out of University College London, ViaNautis develops targeted polymer nanovesicles (tPNVs) via its proprietary polyNaut platform. The technology enables non-viral, nanobody-guided delivery of DNA and mRNA payloads to specific tissues. In spinal cord injury, targeted delivery remains a primary barrier to therapeutic progress; the polyNaut system is designed to deliver regenerative payloads directly to defined cell populations around injury sites while avoiding the immunogenicity and cargo size constraints of traditional viral vectors.
The funding builds on ViaNautis’ broader central nervous system (CNS) pipeline, alongside ongoing programmes in immunology, oncology, and respiratory disease. The company previously raised a £20 million Series A round in November 2023 backed by 4BIO Capital, BGF and UCB Ventures, and maintains active strategic partnerships with Eli Lilly and the Cystic Fibrosis Foundation.
“Spinal cord injury is one of the clearest examples of a disease area where delivery remains a key limiting factor,” said chief executive Adi Hoess. “PolyNaut was designed to overcome these challenges precisely by enabling targeted, non-viral systemic delivery of regenerative payloads to defined cell populations at or around the lesion site.”
Scan.com raises $220 million to scale US diagnostic imaging network
London-headquartered medical imaging platform Scan.com has closed $220 million (£168 million) in a combined equity and debt financing package to fund its expansion across the US.
The deal comprises a $90 million Series C equity round led by French growth investor Noteus Partners, alongside $130 million in debt facilities provided by VerisFi Capital and Atempo Growth to support working capital and targeted acquisitions.
The equity round drew participation from corporate and institutional backers, including Aviva Investors, Concord Health Partners, YZR Capital, and Oxford Capital.
Founded in 2021 by Charlie Bullock, Oliver Knight, Joe Daniels, Jasper Nissim and Khalid Latief.
Scan.com operates a digital diagnostic infrastructure layer that connects patients, healthcare providers, and independent imaging centres. The company’s API connects directly with radiology scheduling software and electronic medical records, enabling health plans, digital health providers and self-insured employers to book scans, handle administrative intake and route reports through a single interface. The platform incorporates agentic AI to match patient referrals with live scanner availability, pricing, and subspecialty radiologists, while care guides assist patients through scheduling.
Having established itself as the UK’s largest private medical imaging network, Scan.com expanded into the US in 2023. The startup has doubled its annual revenue over the past year, surpassing a $165 million annualised run rate and processing more than 900,000 patients globally to date. Proceeds will be used to expand provider connectivity across the US market and advance its core API and AI routing software.
“The US runs around 600 million medical imaging scans a year, and there is still no national infrastructure behind them,” said Bullock. “An employer, a health plan or a digital health app can now connect to imaging capacity nationwide through a single API, and their patients get scanned at a quality-checked centre in days rather than weeks, at a price they can see before they schedule. This investment is about making that the standard in US healthcare, rather than the exception.”
Mater Private Network completes €520 million refinancing
Irish private hospital group Mater Private Network has completed a €520 million (£438 million) senior secured long-term refinancing. Backed by French private equity infrastructure manager InfraVia Capital Partners, the seven-year debt package replaces its 2022 financing facility and incorporates an additional capital expenditure facility to support ongoing expansion across its 11 clinical locations in Ireland.
The syndicated transaction was underwritten by a consortium of five commercial banks – AIB, Bank of Ireland, Intesa Sanpaolo, Nord/LB and Alpha Bank – alongside institutional infrastructure debt funds managed by BNP Paribas Asset Management and Edmond de Rothschild Asset Management.
Mater Private Network specialises in cardiovascular, oncology, spinal and orthopaedic care. The new debt structure will fund investments in clinical capacity – including surgical theatres, catheterisation laboratories and robotic surgery suites – while accelerating the group’s ongoing rollout of an enterprise Electronic Health Record (EHR) system and patient digital health portal.
“Securing this refinancing with a diversified pool of leading banks and institutional infrastructure debt investors is a strong endorsement of Mater Private Network’s quality, resilience and long-term growth prospects,” said Pauline Fiastre, financing director at InfraVia. “The new financing structure provides the flexibility and capacity required to support the company’s continued investment in high-quality patient care across Ireland and the next phase of development.”
Claret Capital Partners closes €575 million Fund IV for European growth debt
London-headquartered growth debt fund manager Claret Capital Partners has held the final close of its Claret European Growth Capital Fund IV at €575 million (£485 million), surpassing its initial €500 million target. The fund comprises €440 million in core fund commitments alongside €135 million in discretionary co-investment mandates, bringing Claret’s total capital raised since inception to €1.3 billion.
The vehicle attracted capital from pension funds, insurers, family offices and institutional investors, alongside private wealth backing via a European Long-Term Investment Fund (ELTIF) structure.
Claret provides non-dilutive term loans ranging from €2 million to €100 million for high-growth businesses across life sciences, technology and impact sectors. The firm has already deployed 32% of Fund IV across 27 companies – including clinical-stage drug developers Inventiva and Cinclus Pharma, as well as medtech group SIS Medical – to fund international expansion, strategic acquisitions and research and development.
Proceeds from the final close will support the expansion of Claret’s pan-European platform, following recent team additions in Paris and upcoming expansion in Berlin. The fund builds on the performance of Fund III, which closed at €297 million in 2022 and backed European life sciences and technology exits including Endomag, Cytora and Abivax.
“As equity markets remain more selective and founders look for ways to grow without unnecessary dilution, we expect demand for flexible, non-dilutive capital to keep accelerating,” said Johan Kampe, managing partner at Claret Capital Partners. “Fund IV positions us to meet that demand at scale.”
